Search results


Therapeutic Response

Precision oncology relationships indicating that patients with listed biomarkers and diagnosed cancer type may be sensitive to the listed therapies.

Filter by organization:
Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) KRAS p.G12C Non-Small Cell Lung Cancer Adagrasib
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine
FDA (1) HC (1) EGFR somatic variants Non-Small Cell Lung Cancer Afatinib
FDA (2) HC (1) v::ALK Non-Small Cell Lung Cancer Alectinib
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HC (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Amivantamab
FDA (2) PML::RARA APL with PML-RARA Arsenic trioxide
FDA (2) BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) ABL1 p.T315I, BCR::ABL1 Chronic Myelogenous Leukemia Asciminib
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) HC (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Atezolizumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab
FDA (1) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (1) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (1) PDGFRA p.D842V Gastrointestinal Stromal Tumor Avapritinib
FDA (2) HC (2) BRAF p.V600E Melanoma Binimetinib, Encorafenib
FDA (2) HC (1) BRAF p.V600K Melanoma Binimetinib, Encorafenib
FDA (2) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
FDA (2) HC (1) CD19 + Acute Lymphoid Leukemia Blinatumomab
FDA (1) BCR::ABL1, CD19 + Acute Lymphoid Leukemia Blinatumomab
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Bosutinib
FDA (1) HC (1) CD30 + Anaplastic Large Cell Lymphoma Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
FDA (1) CD30 + Anaplastic Large Cell Lymphoma Brentuximab vedotin
FDA (1) HC (1) v::ALK Non-Small Cell Lung Cancer Brigatinib
FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
FDA (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HC (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Capmatinib
FDA (1) HC (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Capmatinib
FDA (1) HC (1) Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Carboplatin, Cemiplimab, Pemetrexed
FDA (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR Non-Small Cell Lung Cancer Cemiplimab
FDA (1) HC (2) v::ALK Non-Small Cell Lung Cancer Ceritinib
FDA (1) HC (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) HC (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (1) HC (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
FDA (2) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
FDA (1) HC (1) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
FDA (1) HC (1) BRAF p.V600K Melanoma Cobimetinib, Vemurafenib
FDA (1) HC (1) v::ALK Non-Small Cell Lung Cancer Crizotinib
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Crizotinib
FDA (1) v::ALK Anaplastic Large Cell Lymphoma Crizotinib
FDA (1) v::ALK Inflammatory Myofibroblastic Tumor Crizotinib
FDA (1) HC (1) BRAF p.V600E Melanoma Dabrafenib
FDA (4) BRAF p.V600E Melanoma Dabrafenib, Trametinib
FDA (4) BRAF p.V600K Melanoma Dabrafenib, Trametinib
FDA (2) HC (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Anaplastic Thyroid Cancer Dabrafenib, Trametinib
FDA (2) BRAF p.V600E Any solid tumor Dabrafenib, Trametinib
FDA (2) HC (2) BRAF p.V600E Low-Grade Glioma, NOS Dabrafenib, Trametinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Dacomitinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Dacomitinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Dasatinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (2) BCR::ABL1 Acute Lymphoid Leukemia Dasatinib
FDA (1) dMMR Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
FDA (1) MSI-H Endometrial Carcinoma Carboplatin, Dostarlimab, Paclitaxel
FDA (1) HC (1) dMMR Endometrial Carcinoma Dostarlimab
FDA (1) dMMR Any solid tumor Dostarlimab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1) HC (1) dMMR Endometrial Carcinoma Carboplatin, Durvalumab, Paclitaxel
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant
FDA (1) IDH2 p.R140Q Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140L Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140G Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R140W Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172K Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172M Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172G Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172S Acute Myeloid Leukemia Enasidenib
FDA (1) IDH2 p.R172W Acute Myeloid Leukemia Enasidenib
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Entrectinib
FDA (1) HC (1) v::NTRK1 Any solid tumor Entrectinib
FDA (1) HC (1) v::NTRK2 Any solid tumor Entrectinib
FDA (1) HC (1) v::NTRK3 Any solid tumor Entrectinib
FDA (1) HC (1) FGFR3 p.R248C Bladder Urothelial Carcinoma Erdafitinib
FDA (1) HC (1) FGFR3 p.S249C Bladder Urothelial Carcinoma Erdafitinib
FDA (1) HC (1) FGFR3 p.G370C Bladder Urothelial Carcinoma Erdafitinib
FDA (1) HC (1) FGFR3 p.Y373C Bladder Urothelial Carcinoma Erdafitinib
FDA (1) HC (1) FGFR3::TACC3 Bladder Urothelial Carcinoma Erdafitinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive Invasive Breast Carcinoma Fulvestrant
FDA (1) PR positive Invasive Breast Carcinoma Fulvestrant
FDA (1) ER positive, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (2) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (2) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
FDA (1) FGFR2::v Intrahepatic Cholangiocarcinoma Futibatinib
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Gefitinib
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Gefitinib
FDA (2) CD33 + Acute Lymphoid Leukemia Gemtuzumab ozogamicin
FDA (1) FLT3-ITD Acute Lymphoid Leukemia Gilteritinib
FDA (1) FLT3 p.D835Y Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835A Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835E Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835H Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835N Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835S Acute Lymphoid Leukemia Gilteritinib
FDA (1) HC (1) FLT3 p.D835V Acute Lymphoid Leukemia Gilteritinib
FDA (2) HC (2) BCR::ABL1 Chronic Myelogenous Leukemia Imatinib
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (2) HC (2) BCR::ABL1 Acute Lymphoid Leukemia Imatinib
FDA (1) HC (1) PDGFRA rearrangements Myelodysplastic Syndromes Imatinib
FDA (1) HC (1) PDGFRB rearrangements Myelodysplastic Syndromes Imatinib
FDA (1) HC (1) KIT p.D816V Aggressive Systemic Mastocytosis Imatinib
FDA (1) HC (1) FIP1L1::PDGFRA Chronic Eosinophilic Leukemia, NOS Imatinib
FDA (1) HC (2) CD117 + Gastrointestinal Stromal Tumor Imatinib
FDA (1) FIP1L1::PDGFRA Gastrointestinal Stromal Tumor Imatinib
FDA (1) FGFR2::v Cholangiocarcinoma Infigratinib
FDA (1) HC (1) CD22 + Acute Lymphoid Leukemia Inotuzumab ozogamicin
FDA (2) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) HC (2) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (2) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (2) IDH1 p.R132C Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132G Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132H Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132L Acute Myeloid Leukemia Ivosidenib
FDA (2) IDH1 p.R132S Acute Myeloid Leukemia Ivosidenib
FDA (1) HC (1) IDH1 p.R132C Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) HC (1) IDH1 p.R132G Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) HC (1) IDH1 p.R132H Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) HC (1) IDH1 p.R132L Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) HC (1) IDH1 p.R132S Acute Myeloid Leukemia Azacitidine, Ivosidenib
FDA (1) IDH1 p.R132C Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132G Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132H Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132L Myelodysplastic Syndromes Ivosidenib
FDA (1) IDH1 p.R132S Myelodysplastic Syndromes Ivosidenib
FDA (1) HC (1) IDH1 p.R132C Cholangiocarcinoma Ivosidenib
FDA (1) HC (1) IDH1 p.R132G Cholangiocarcinoma Ivosidenib
FDA (1) HC (1) IDH1 p.R132H Cholangiocarcinoma Ivosidenib
FDA (1) HC (1) IDH1 p.R132L Cholangiocarcinoma Ivosidenib
FDA (1) HC (1) IDH1 p.R132S Cholangiocarcinoma Ivosidenib
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HC (1) v::NTRK1 Any solid tumor Larotrectinib
FDA (1) HC (1) v::NTRK2 Any solid tumor Larotrectinib
FDA (1) HC (1) v::NTRK3 Any solid tumor Larotrectinib
FDA (1) HC (1) 5q deletion Myelodysplastic Syndromes Lenalidomide
FDA (1) HC (2) v::ALK Non-Small Cell Lung Cancer Lorlatinib
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine
FDA (1) HC (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835Y Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835A Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835E Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835H Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835N Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835S Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.D835V Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) HC (1) FLT3 p.I836del Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) CDK12 oncogenic variants Acute Myeloid Leukemia Cytarabine, Daunorubicin, Midostaurin
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Mobocertinib
FDA (1) HER2-positive Invasive Breast Carcinoma Neratinib
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
FDA (3) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
FDA (3) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Nivolumab, Paclitaxel
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Ipilimumab, Nivolumab
FDA (2) HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
FDA (2) HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (2) HC (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (2) HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (2) HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HRD Ovarian Epithelial Tumor Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HRD High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HC (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (1) HRD Peritoneal Serous Carcinoma Bevacizumab, Olaparib
FDA (2) HC (2) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
FDA (2) HC (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
FDA (1) HC (1) BRCA1 pathogenic variants Pancreatic Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) ATM pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) ATM oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BARD1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRIP1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK1 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) FANCL oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51B oncogenic variants Prostate Adenocarcinoma Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD51D oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) RAD54L oncogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) HC (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) HC (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) HC (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) HC (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) IDH1 p.R132C Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132G Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132H Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132L Acute Myeloid Leukemia Olutasidenib
FDA (1) IDH1 p.R132S Acute Myeloid Leukemia Olutasidenib
FDA (3) HC (3) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Osimertinib
FDA (3) HC (3) EGFR p.L858R Non-Small Cell Lung Cancer Osimertinib
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Carboplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Cisplatin, Osimertinib, Pemetrexed
FDA (1) HC (1) EGFR p.T790M Non-Small Cell Lung Cancer Osimertinib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pembrolizumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed
FDA (1) HC (1) PD-L1 >= 1%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Pembrolizumab
FDA (1) HC (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Pembrolizumab
FDA (2) HC (1) PD-L1 (CPS) >= 1 Head and Neck Squamous Cell Carcinoma Pembrolizumab
FDA (1) HC (1) dMMR Any solid tumor Pembrolizumab
FDA (1) HC (1) MSI-H Any solid tumor Pembrolizumab
FDA (1) HC (1) dMMR Colorectal Adenocarcinoma Pembrolizumab
FDA (1) HC (1) MSI-H Colorectal Adenocarcinoma Pembrolizumab
FDA (1) HC (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (1) HC (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (1) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Pembrolizumab
FDA (1) PD-L1 (CPS) >= 10 Esophageal Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Adenocarcinoma Pembrolizumab
FDA (1) PD-L1 (CPS) >= 1 Cervical Squamous Cell Carcinoma Pembrolizumab
FDA (1) MSI-L Endometrial Carcinoma Lenvatinib, Pembrolizumab
FDA (1) pMMR Endometrial Carcinoma Pembrolizumab
FDA (1) MSI-H Endometrial Carcinoma Pembrolizumab
FDA (1) TMB-H (>= 10 mutations / Mb) Any solid tumor Pembrolizumab
FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
FDA (1) HC (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
FDA (1) HC (1) FGFR2::v Cholangiocarcinoma Pemigatinib
FDA (1) HC (1) FGFR2 rearrangements Cholangiocarcinoma Pemigatinib
FDA (1) FGFR1 rearrangements Myeloid/Lymphoid Neoplasms Pemigatinib
FDA (2) HC (5) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) BCR::ABL1 Acute Lymphoid Leukemia Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (1) HC (1) ABL1 p.T315I, BCR::ABL1 Acute Lymphoid Leukemia Ponatinib
FDA (1) HC (1) ABL1 p.T315I Chronic Myelogenous Leukemia Ponatinib
FDA (1) v::RET Non-Small Cell Lung Cancer Pralsetinib
FDA (1) v::RET Papillary Thyroid Cancer Pralsetinib
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Erlotinib, Ramucirumab
FDA (1) HC (1) v::ROS1 Non-Small Cell Lung Cancer Repotrectinib
FDA (1) v::NTRK1 Any solid tumor Repotrectinib
FDA (1) v::NTRK2 Any solid tumor Repotrectinib
FDA (1) v::NTRK3 Any solid tumor Repotrectinib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) CD20 + Non-Hodgkin Lymphoma Rituximab
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Burkitt Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Mature B-Cell Neoplasms Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine, Rituximab
FDA (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
FDA (1) HC (1) v::RET Non-Small Cell Lung Cancer Selpercatinib
FDA (1) HC (1) RET oncogenic variants Medullary Thyroid Cancer Selpercatinib
FDA (1) v::RET Anaplastic Thyroid Cancer Selpercatinib
FDA (1) v::RET Any solid tumor Selpercatinib
FDA (1) HC (1) KRAS p.G12C Non-Small Cell Lung Cancer Sotorasib
FDA (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) HC (1) MET Exon 14 (Splice Site) Non-Small Cell Lung Cancer Tepotinib
FDA (1) HC (1) MET Exon 14 (Deletion) Non-Small Cell Lung Cancer Tepotinib
FDA (1) HC (1) BRAF p.V600E Melanoma Trametinib
FDA (1) HC (1) BRAF p.V600K Melanoma Trametinib
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (1) HER2-positive Gastrointestinal Stromal Tumor Trastuzumab
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) HC (1) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) ERBB2 oncogenic variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
FDA (1) HER2-positive Any solid tumor Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
FDA (1) HC (1) BRAF p.V600E Melanoma Vemurafenib
FDA (1) BRAF p.V600E Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
FDA (1) BRAF p.V600K Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease Vemurafenib
FDA (1) EZH2 p.Y646N Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646F Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646H Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646S Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.Y646C Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.A862G Follicular Lymphoma Tazemetostat
FDA (1) EZH2 p.A692V Follicular Lymphoma Tazemetostat
FDA (1) BRCA1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATM oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CDK12 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) ATR pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) CHEK2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) FANCA pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) PALB2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MLH1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) RAD51C oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) MRE11 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) NBN pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (1) TSC1 oncogenic variants Renal Angiomyolipoma Everolimus
FDA (1) TSC2 oncogenic variants Renal Angiomyolipoma Everolimus
FDA (1) TSC1 oncogenic variants Anaplastic Thyroid Cancer Everolimus
FDA (1) TSC2 oncogenic variants Anaplastic Thyroid Cancer Everolimus
FDA (1) CDK12 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
FDA (2) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Lazertinib
FDA (2) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Lazertinib
FDA (1) HC (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) HC (1) EGFR p.L858R Non-Small Cell Lung Cancer Amivantamab, Carboplatin, Pemetrexed
FDA (1) FOLR1 positive Ovarian Epithelial Tumor Mirvetuximab soravtansine
FDA (1) FOLR1 positive High-Grade Serous Fallopian Tube Cancer Mirvetuximab soravtansine
FDA (1) FOLR1 positive Peritoneal Serous Carcinoma Mirvetuximab soravtansine
FDA (1) BRAF rearrangements Low-Grade Glioma, NOS Tovorafenib
FDA (1) v::BRAF Low-Grade Glioma, NOS Tovorafenib
FDA (1) BRAF p.V600E Low-Grade Glioma, NOS Tovorafenib
FDA (1) BRAF p.V600K Low-Grade Glioma, NOS Tovorafenib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Gemcitabine
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Durvalumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Pemetrexed
FDA (1) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
FDA (1) HC (1) IDH1 p.R132C Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132G Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132H Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132L Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132S Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172K Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172M Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172G Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172S Astrocytoma Vorasidenib
FDA (1) HC (1) IDH2 p.R172W Astrocytoma Vorasidenib
FDA (1) HC (1) IDH1 p.R132C Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132G Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132H Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132L Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH1 p.R132S Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172K Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172M Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172G Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172S Oligodendroglioma Vorasidenib
FDA (1) HC (1) IDH2 p.R172W Oligodendroglioma Vorasidenib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Nivolumab, Pemetrexed
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Gemcitabine, Nivolumab
FDA (2) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) MSI-H Colorectal Adenocarcinoma Nivolumab
FDA (1) dMMR Colorectal Adenocarcinoma Nivolumab
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (1) HC (1) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
FDA (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
FDA (1) HC (1) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
FDA (1) HER2-positive Intraductal Papillary Neoplasm of the Bile Duct Zanidatamab
FDA (1) HER2-positive Intracholecystic Papillary Neoplasm Zanidatamab
FDA (1) HER2-positive Cholangiocarcinoma Zanidatamab
FDA (1) v::NRG1 Non-Small Cell Lung Cancer Zenocutuzumab
FDA (1) v::NRG1 Pancreatic Adenocarcinoma Zenocutuzumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Ensartinib
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
FDA (2) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
FDA (1) t(KMT2A;v) Acute Lymphoid Leukemia Revumenib
FDA (1) t(KMT2A;v) Acute Myeloid Leukemia Revumenib
FDA (1) t(KMT2A;v) Burkitt Lymphoma Revumenib
FDA (1) t(KMT2A;v) Acute Leukemias of Ambiguous Lineage Revumenib
HC (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Gefitinib
HC (1) EGFR oncogenic variants Non-Small Cell Lung Cancer Afatinib
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
HC (1) PDGFRA rearrangements Myeloproliferative Neoplasm Imatinib
HC (1) PDGFRB rearrangements Myeloproliferative Neoplasm Imatinib
HC (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Durvalumab, Tremelimumab
HC (1) MSI-H Endometrial Carcinoma Dostarlimab
HC (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 Non-Small Cell Lung Cancer Cemiplimab
HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
HC (1) CD33 + Acute Myeloid Leukemia Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
HC (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
HC (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (2) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Ipilimumab, Nivolumab
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Nivolumab
HC (1) v::RET Papillary Thyroid Cancer Selpercatinib
HC (2) BRAF p.V600E High-Grade Glioma, NOS Dabrafenib, Trametinib
HC (1) BRAF p.V600K Melanoma Dabrafenib
HC (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
HC (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
HC (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
HC (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
HC (1) FLT3-ITD Acute Myeloid Leukemia Gilteritinib
HC (1) FLT3 p.D835Y Acute Myeloid Leukemia Gilteritinib
HC (1) BRAF p.V600K Melanoma Vemurafenib
HC (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) 17p deletion Chronic Lymphocytic Leukemia Ibrutinib
HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HC (1) PD-L1 >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Nivolumab, Oxaliplatin
HC (1) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
HC (1) CD20 + Follicular Lymphoma Rituximab
FDA (1) v::ROS1 Non-Small Cell Lung Cancer Taletrectinib
FDA (1) c-Met >= 50% Lung Non-Squamous Non-Small Cell Carcinoma Telisotuzumab Vedotin
FDA (1) KRAS p.G12C Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib
FDA (1) KRAS p.G12V Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib
FDA (2) t(15;17) APL with PML-RARA Arsenic trioxide
HC (1) CD30 + Mycosis Fungoides Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab
HC (1) BRAF p.V600E Melanoma Pembrolizumab
HC (1) BRAF p.V600K Melanoma Pembrolizumab
HC (1) BRAF p.V600E Melanoma Nivolumab
HC (1) BRAF p.V600K Melanoma Nivolumab
HC (1) CD30 + Angioimmunoblastic T-Cell Lymphoma Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
HC (1) CD30 + Peripheral T-Cell lymphoma, NOS Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
FDA (1) EGFR somatic variants Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 19 (Deletion) Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.L858R Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR p.T790M Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (1) EGFR Exon 20 (Insertion) Non-Small Cell Lung Cancer Sunvozertinib
FDA (1) ERBB2 TKD activating variants Lung Non-Squamous Non-Small Cell Carcinoma Zongertinib
FDA (1) H3-3A p.K27M Diffuse Midline Glioma Dordaviprone
FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (1) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
FDA (1) FLT3-ITD Acute Myeloid Leukemia Quizartinib
FDA (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Daunorubicin, Quizartinib
FDA (1) FLT3-ITD Acute Myeloid Leukemia Cytarabine, Idarubicin, Quizartinib
FDA (1) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Ziftomenib
FDA (1) ERBB2 TKD activating variants Lung Non-Squamous Non-Small Cell Carcinoma Sevabertinib
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan
FDA (1) NPM1 p.W288Cfs*12 Acute Myeloid Leukemia Revumenib
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (1) NPM1 p.W288Cfs*12 Acute Lymphoid Leukemia Revumenib
FDA (1) NPM1 p.W288Cfs*12 Burkitt Lymphoma Revumenib
FDA (1) NPM1 p.W288Cfs*12 Acute Leukemias of Ambiguous Lineage Revumenib